23/06/2025
How are the 2025 predictions materializing? At the beginning of the year, our Life Sciences & Healthcare team presented a comprehensive overview of the main trends that would shape the sector regulated by Anvisa and ANS in 2025, which you can find here. Now, several months later, it is time to examine the present and …
18/06/2025
In a highly significant move for the clinical trial sector in Brazil, the National Congress has made a decision that could directly impact the future of scientific innovation and access to experimental treatments in the country. The overturning of the presidential veto on the Clinical Trial Law marks a new chapter in the regulation of …
12/05/2025
On May 5, 2025, Public Consultation 1,330/2025 of the Brazilian Drug Market Regulation Chamber (CMED) was published in the Federal Register, opening a 60-day period for submitting comments on the text of the proposed revision of CMED Resolution 02/2004, which deals with the criteria for defining prices of new products and new presentations of medicines. …
30/04/2025
A partir de 26 de maio de 2025, riscos psicossociais — como assédio moral e sexual, síndrome de burnout, carga excessiva de trabalho e fragilidades na comunicação e gestão — passam a ser reconhecidos oficialmente como fatores que impactam a saúde e segurança do trabalhador, ao lado dos já tradicionais riscos físicos, químicos, biológicos e ergonômicos. …
03/04/2025
On April 3, 2025, the rankings for the Contentious 2025 cycle of the Chambers Brazil guide were released. This year, we are proud to be among the leading law firms with the highest number of ranked departments and lawyers. We have been recognized in 8 practice area rankings and received 11 individual recognitions for our …
28/03/2025
On March 26th, 2025, Anvisa’s Board of Directors (“DICOL”) approved the opening of a Public Consultation (“PC”) to review the regulation of cannabis-based products. The PC was published on March 28th, and interested parties can submit contributions until June 6th, 2025. What happened? The proposal to revise RDC 327/2019 includes significant changes, such as allowing …
20/02/2025
A decision by the Superior Court of Justice (STJ) determined that the Brazilian Health Regulatory Agency (Anvisa) must issue regulations regarding the importation, planting, cultivation, industrialization, and commercialization of hemp for medicinal, pharmaceutical, and industrial purposes. For those less familiar, hemp is a plant from the botanical class of Cannabis sativa cultivars. As recognized in …
18/02/2025
We are proud to announce that our partner Leticia Provedel was the winner of The Legal 500 Brazil Awards 2025, in the category ‘Intellectual Property Lawyer of the Year’. The award ceremony took place last week, on February 13, 2025, in São Paulo. We congratulate Leticia and the entire team on this achievement!
13/02/2025
Chambers & Partners announced the results of the Chambers Global 2025 guide on February 13th, 2025, showcasing our performance on the global stage. This year, 7 of our practice areas received recognition and 10 of our lawyers have been individually recognized across 12 practice areas. See the consolidated results below. Ranked practice areas: Corporate/M&A: Highly …
11/02/2025
On Friday, February 7th, the Pharmaceutical Market Regulation Chamber (CMED) published in the Federal Register the Notice of Call #1/2025, which aims to collect data, information, opinions and suggestions from society on the criteria that should be established in the pricing of advanced therapy products. Such information will support the preparation of the Regulatory Impact Analysis …